Salt-Sensitivity and Immunity Cell Activation
Launched by VANDERBILT UNIVERSITY MEDICAL CENTER · Nov 21, 2018
Trial Information
Current as of July 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, titled "Salt-Sensitivity and Immunity Cell Activation," is investigating how salt affects blood pressure and related health issues. It aims to understand why some people with high blood pressure, known as hypertension, are more sensitive to salt than others. The researchers believe that certain immune cells called monocytes react to salt in a way that might be connected to high blood pressure. By studying these cells, the team hopes to find a simpler method for identifying individuals who are sensitive to salt and may benefit from reducing their salt intake.
To participate in the trial, individuals must be between 18 and 60 years old and have a diagnosis of high blood pressure, which means their blood pressure readings are above 140/90 mmHg or they are taking medications for hypertension. Participants should also have a healthy weight, as defined by a Body Mass Index (BMI) of 18.5 to 24.9. The study will involve 20 participants, and those who join can expect to undergo tests that assess their body's response to salt. It’s important to note that people with certain conditions, like recent heart problems, diabetes, or pregnant women, will not be eligible to participate.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • We will perform a pilot analysis in 20 hypertensive subjects controlled for gender (50% men, 50% women), age (18-60 years),
- • New or pre-existing diagnosis of essential hypertension defined as systolic blood pressure \>140 mmHg or \>90 mmHg diastolic or taking antihypertensive medications regardless of current blood pressure.
- • BMI (18.5-24.9).
- • Only subjects who give informed consent will be studied.
- Exclusion Criteria:
- • Acute cardiovascular event(s) within the previous 6 months
- • Claustrophobia precluding obtaining an MRI
- • Inability to understand the nature, scope, and possible consequences of the study or to participate in/comply with the protocol.
- • Current excessive alcohol or illicit drug use.
- • Blood pressure below the inclusion criteria levels after discontinuation of therapy
- • Presence of metal implants such as artificial joints.
- • Concomitant diabetes mellitus, type I or II.
- • Autoimmune disease.
- • Recent vaccination
- • Younger or older that inclusion criteria.
- • Pregnancy.
About Vanderbilt University Medical Center
Vanderbilt University Medical Center (VUMC) is a leading academic medical center located in Nashville, Tennessee, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, VUMC integrates cutting-edge scientific inquiry with patient-centered care, supporting a diverse array of studies aimed at enhancing medical knowledge and improving treatment outcomes. With a robust infrastructure and a multidisciplinary team of experts, VUMC fosters collaboration across various fields, ensuring the highest standards of safety and ethical considerations in its research endeavors. Through its dedication to medical discovery and education, VUMC plays a pivotal role in shaping the future of medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nashville, Tennessee, United States
Patients applied
Trial Officials
Annet Kirabo
Principal Investigator
Vanderbilt University Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials